Indoco Remedies Stock Slides 3% As Goa Facility Gets Four Observations From USFDA
In the early hours of trade on Friday Indoco Remedies, an Indian pharmaceutical's stock dipped by 4.12 per cent on account of an inspection by the top US regulatory authority.
Indoco Remedies on Thursday notified the exchanges that its solid oral formulation facility located at Goa was inspected by the United States Food and Drug Administration (USFDA) ) from October 12, 2023, to October 18, 2023.
The company said that the USFDA carried out a pre-approval inspection that was conducted for two drug product applications filed from this facility. During the inspection, the USFDA highlighted four observations under the regulator's rulebook's Form 483.
The company said in a statement that it is committed to addressing the observations comprehensively and within the stipulated time.
